GREY:IMVIF - Post by User
Comment by
Breakthoroughon Dec 05, 2020 1:19am
167 Views
Post# 32043247
RE:RE:RE:RE:RE:Comparison with STR-002
RE:RE:RE:RE:RE:Comparison with STR-002Of course. And the distribution of the 10 is 3 over 12 months, 6 over 6 months, 1 below 6 months. The total number of 4 that have reached 12 months include 3 ongoing. It means thay only 7 of the ongoing 10 could (in the best of cases) add to these four. The final number will be between 11 (36%) and 4 (13%). A different thing is that in the dose-expansion trial the numbers become a bit better, due to the optimization of dose and the inclussion of less heavily pre-treated parients. They anticipate preliminary data by the 2nd half of 2021, and a meeting with the FDA in the 2nd half of 2021.